Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EVO | 6-K | bearish | 5/10 | Evotec SE released preliminary unaudited nine-months 2026 results showing Group revenues of approximately €465.0 million | Oct 14, 2026 |
| LEXX | EFFECT | bearish | 5/10 | The SEC declared effective Lexaria Bioscience Corp.'s S-3 shelf registration (File No. 333-299257) on October 13, 2026. | Oct 14, 2026 |
| LQDA | 8-K | mixed | 7/10 | Liquidia entered into a global settlement with United Therapeutics (UTC) resolving all six pending lawsuits, including p | Oct 13, 2026 |
| IMMP | 6-K | neutral | 4/10 | Immutep received Nasdaq notification confirming it has regained compliance with the minimum bid price requirement (Rule | Oct 13, 2026 |
| CUE | 144 | neutral | 2/10 | Sumita Ray, Corporate Secretary of Cue Biopharma, filed a Form 144 notice to sell 1,844 shares of common stock (~$51,724 | Oct 13, 2026 |
| ONMD | CLUSTER | bullish | 6/10 | Two insiders at OneMedNet Corp, including a director/10% owner and the Chief Medical Officer, made open-market purchases | Oct 13, 2026 |
| GILD | COURT-RULING | neutral | 2/10 | A federal district court dismissed with prejudice all claims by pro se plaintiff Diana Cash against Gilead Sciences, fin | Oct 13, 2026 |
| LQDA | CLUSTER | neutral | 4/10 | Two Liquidia Corp insiders (Chief Business Officer and Chief Accounting Officer) sold a combined $376K in open-market sa | Oct 13, 2026 |
| RYTM | PRESS-RELEASE | bullish | 6/10 | Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan for acquired hypothalamic ob | Oct 13, 2026 |
| SLN | SC 13G/A | neutral | 3/10 | Tetragon Financial Management LP and related entities filed an amended Schedule 13G disclosing a 5.3% passive stake in S | Oct 13, 2026 |
| RTSN | CLUSTER | bullish | 5/10 | Two insiders at Retension Pharmaceuticals, including CEO Eric Keller and Director Franklin Berger, made open-market purc | Oct 13, 2026 |
| RTSN | 3 | neutral | 2/10 | Pavan Cheruvu filed a Form 3 initial statement of beneficial ownership with Retension Pharmaceuticals, Inc., appointing | Oct 13, 2026 |
| PCRX | SC 13D/A | bearish | 7/10 | DOMA Perpetual Capital Management and its affiliates have fully exited their stake in Pacira BioSciences, selling all 2, | Oct 13, 2026 |
| BMEA | 8-K | bullish | 6/10 | Biomea Fusion reported Phase 1 topline data for BMF-650, its next-generation oral GLP-1 receptor agonist for obesity. In | Oct 13, 2026 |
| AGMB | 6-K | bullish | 5/10 | Agomab announced the first patient dosed in the global NOV-ERA Phase 2b study of ontunisertib for fibrostenosing Crohn's | Oct 13, 2026 |
| TARS | S-3ASR | neutral | 4/10 | Tarsus Pharmaceuticals filed an automatic shelf registration statement (S-3ASR) to register up to 2,908,692 shares of co | Oct 13, 2026 |
| GTBP | DEF 14A | bearish | 7/10 | GT Biopharma is holding a special meeting on November 11, 2026 to vote on four proposals: (1) cleaning up obsolete prefe | Oct 13, 2026 |
| PVLA | 144 | neutral | 4/10 | Director George M. Jenkins filed a Form 144 notice of intent to sell 27,500 shares of Palvelia Therapeutics common stock | Oct 13, 2026 |
| BHST | 6-K | bullish | 5/10 | BioHarvest Sciences announced that its proprietary Olive Cell composition has reached commercial readiness, completing d | Oct 13, 2026 |
| LKFT | 6-K | neutral | 2/10 | Lakefront Biotherapeutics disclosed the repurchase of 126,322 of its own ordinary shares between October 5 and October 9 | Oct 13, 2026 |
| CDXS | 144 | neutral | 2/10 | Georgia Erbez, an officer of Codexis, filed a Form 144 notice of intent to sell 6,335 shares of common stock, valued at | Oct 13, 2026 |
| RVMD | 8-K | bullish | 6/10 | Revolution Medicines triggered a $250M Tranche A loan draw from Royalty Pharma upon FDA approval of RASONQUE (daraxonras | Oct 13, 2026 |
| TARS | S-3ASR | neutral | 3/10 | Tarsus Pharmaceuticals filed an automatic shelf registration statement (S-3ASR) to register up to 2,232,144 shares of co | Oct 13, 2026 |
| GENB | PRESS-RELEASE | bullish | 6/10 | Generate Biomedicines announced a multi-target collaboration with Zealand Pharma to develop multispecific protein therap | Oct 13, 2026 |
| CDXS | 144 | neutral | 2/10 | Director Alison Moore filed a Form 144 notice of intent to sell 6,335 shares of Codexis common stock, valued at approxim | Oct 13, 2026 |
| SBFM | SC 13G | neutral | 4/10 | CVI Investments, Inc. (managed by Heights Capital Management, Inc.) filed a new SC 13G disclosing a 9.9% passive stake i | Oct 13, 2026 |
| MLYS | 144 | neutral | 3/10 | Officer David Malcom Rodman filed a Form 144 notice to sell 3,542 shares of Mineralys Therapeutics common stock, valued | Oct 13, 2026 |
| RDHL | 6-K | bearish | 6/10 | RedHill Biopharma filed a 6-K and prospectus supplement to increase the maximum aggregate offering amount under its exis | Oct 13, 2026 |
| BNTX | 6-K | bearish | 6/10 | BioNTech announced that its Phase 2/3 AHEAD-MERIT trial for mRNA cancer immunotherapy BNT113 in HPV16+ head and neck can | Oct 13, 2026 |
| BMEA | PRESS-RELEASE | neutral | 5/10 | Biomea Fusion announced Phase 1 data for oral GLP-1 RA BMF-650 showing 1.5%-3.2% weight reduction at Day 29 in outpatien | Oct 13, 2026 |